Downgrades Buy Hold X

ALLK Allakos

Jefferies

$6 $1.50

Downgrades Overweight Neutral X

ALLK Allakos

Cantor Fitzgerald

Upgrades Mkt Perform Outperform X

ALLK Allakos

William Blair

Resumed Buy X

ALLK Allakos

Jefferies

$9 $6

Initiated Mkt Outperform X

ALLK Allakos

JMP Securities

$11

Upgrades Hold Buy X

ALLK Allakos

Jefferies

$6 $9

Initiated Overweight X

ALLK Allakos

Piper Sandler

$22

Downgrades Neutral Underperform X

ALLK Allakos

SMBC Nikko

$2

Downgrades Outperform Mkt Perform X

ALLK Allakos

Cowen

Downgrades Buy Hold X

ALLK Allakos

Jefferies

Downgrades Outperform Mkt Perform X

ALLK Allakos

SVB Leerink

$17

Downgrades Outperform Mkt Perform X

ALLK Allakos

William Blair

Initiated Outperform X

ALLK Allakos

Cowen

Initiated Buy X

ALLK Allakos

H.C. Wainwright

$230

Initiated Overweight X

ALLK Allakos

Cantor Fitzgerald

$218

Initiated Buy X

ALLK Allakos

BofA Securities

$145

Initiated Neutral X

ALLK Allakos

Goldman

$31

Initiated Buy X

ALLK Allakos

Jefferies

$53

Initiated Outperform X

ALLK Allakos

William Blair

ALLK  Allakos Inc.

Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in San Carlos, California.